Pancreatic cancer and its metastases might have their days numbered, according to a study published in The Journal of Experimental Medicine.
These images show the high expression levels of IL-17B and its receptor (brown) in pancreatic cancer (left) compared with normal tissue (right).
Credit: Wu et al., 2015
Targeting IL-17B–IL-17RB signaling with an anti–IL-17RB antibody blocks pancreatic cancer metastasis by silencing multiple chemokines . Wu, H.-H., et al. 2015. J. Exp. Med. doi:10.1084/jem.20141702